Fujian Haixi Pharmaceuticals Co., Ltd. (HKG:2637)

Revenue by Segment

Financials in millions CNY. Fiscal year is January - December.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022
Generic Drugs	582.36M	466.68M	-	-
Pharmaceuticals	-	-	316.63M	212.47M
Total	582.36M	466.68M	316.63M	212.47M

Revenue by Geography

Financials in millions CNY. Fiscal year is January - December.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022
Mainland China	582.36M	466.68M	316.63M	212.47M
Total	582.36M	466.68M	316.63M	212.47M

Data Source: S&P Global Market Intelligence Last updated: Jun 30, 2026

Financial data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every three months for this company.

Update frequency:

Quarterly

Last checked:

Sep 2, 2026

Data Sources Report a data error